JP2017525357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525357A5 JP2017525357A5 JP2017508102A JP2017508102A JP2017525357A5 JP 2017525357 A5 JP2017525357 A5 JP 2017525357A5 JP 2017508102 A JP2017508102 A JP 2017508102A JP 2017508102 A JP2017508102 A JP 2017508102A JP 2017525357 A5 JP2017525357 A5 JP 2017525357A5
- Authority
- JP
- Japan
- Prior art keywords
- analog according
- analog
- amino acid
- seq
- autoimmune disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000003053 toxin Substances 0.000 claims 5
- 231100000765 toxin Toxicity 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 125000003636 chemical group Chemical group 0.000 claims 2
- 238000010367 cloning Methods 0.000 claims 2
- 239000013599 cloning vector Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 101001111252 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial Proteins 0.000 claims 1
- 102100023955 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial Human genes 0.000 claims 1
- 101100330292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-12 gene Proteins 0.000 claims 1
- 101100498071 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-17 gene Proteins 0.000 claims 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020081545A JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014903189A AU2014903189A0 (en) | 2014-08-15 | Novel potassium channel blockers | |
| AU2014903189 | 2014-08-15 | ||
| PCT/AU2015/000487 WO2016023072A1 (en) | 2014-08-15 | 2015-08-14 | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081545A Division JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525357A JP2017525357A (ja) | 2017-09-07 |
| JP2017525357A5 true JP2017525357A5 (enExample) | 2018-09-20 |
| JP6847828B2 JP6847828B2 (ja) | 2021-03-24 |
Family
ID=55303691
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017508102A Active JP6847828B2 (ja) | 2014-08-15 | 2015-08-14 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
| JP2020081545A Active JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020081545A Active JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10246496B2 (enExample) |
| EP (1) | EP3180365B1 (enExample) |
| JP (2) | JP6847828B2 (enExample) |
| AU (1) | AU2015303825B2 (enExample) |
| WO (1) | WO2016023072A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015303825B2 (en) * | 2014-08-15 | 2021-01-14 | Baylor College Of Medicine | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
| KR102533290B1 (ko) * | 2022-04-14 | 2023-05-16 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드 |
| KR102553070B1 (ko) * | 2022-06-16 | 2023-07-07 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5118969B2 (ja) * | 2004-10-07 | 2013-01-16 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法 |
| AR063384A1 (es) | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| CA2686216C (en) * | 2007-05-14 | 2016-04-12 | Universidad Nacional Autonoma De Mexico | Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats |
| EP3385279B1 (en) * | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| AU2012268441B2 (en) * | 2011-06-06 | 2016-05-12 | Kineta One, Llc | ShK-based pharmaceutical compositions and methods of manufacturing and using the same |
| NZ709913A (en) * | 2013-01-25 | 2019-05-31 | Janssen Biotech Inc | Kv1.3 antagonists and methods of use |
| AU2015303825B2 (en) * | 2014-08-15 | 2021-01-14 | Baylor College Of Medicine | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
-
2015
- 2015-08-14 AU AU2015303825A patent/AU2015303825B2/en active Active
- 2015-08-14 EP EP15832619.9A patent/EP3180365B1/en active Active
- 2015-08-14 US US15/503,841 patent/US10246496B2/en active Active
- 2015-08-14 JP JP2017508102A patent/JP6847828B2/ja active Active
- 2015-08-14 WO PCT/AU2015/000487 patent/WO2016023072A1/en not_active Ceased
-
2020
- 2020-05-01 JP JP2020081545A patent/JP6953579B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9221886B2 (en) | Supercharged proteins for cell penetration | |
| JP2017006120A5 (enExample) | ||
| US20110112040A1 (en) | Supercharged proteins for cell penetration | |
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| FI3642340T3 (fi) | Muunneltu l-asparaginaasi | |
| JP2017537611A5 (enExample) | ||
| JP2020023567A5 (enExample) | ||
| IL309801A (en) | Use of protein domains interacting with the nucleosome to enhance targeted genome modification | |
| JP2018528237A5 (enExample) | ||
| Ling et al. | Cathelicidins from the bullfrog Rana catesbeiana provides novel template for peptide antibiotic design | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| JP2013027391A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| SG10201909675QA (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| HRP20151238T1 (hr) | Mutanti frataksina | |
| JP2014529399A5 (enExample) | ||
| JP2017221201A5 (enExample) | ||
| JP2015533791A5 (enExample) | ||
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| SI2718434T1 (en) | Compositions and methods for treating celiac sprue disease | |
| JP2019534884A5 (enExample) | ||
| AR060960A1 (es) | Peptido, polinucleotico, secuencia celula transgenica, huesped viral, celula huesped, vector de expresion, uso y metodo de antagonistas de alta afinidad de quimioquinas elr- cxc | |
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| IL269187B2 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal |